Trial reportDrug design, development and therapy2026
Pharmacokinetics and Renal Safety Evaluation of Colistin Methanesulfonate Sodium in Korean Healthy Male Volunteers: An Open-Label, Multiple-Dose Study.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The objective of this study was to evaluate the pharmacokinetics and renal safety of colistin methanesulfonate sodium (CMS) following single and multiple intravenous administrations in healthy Korean male volunteers. This study provides pharmacokinetic and safety information on an Asian population, where data on polymyxins remain limited. Patients and Methods: This open-label, single- and multiple-dose pharmacokinetic study enrolled 12 subjects, 11 of whom received CMS, and one withdrew prior to dosing. Five doses of CMS 150 mg potency (equivalent to 150 mg colistin) were administered over 2.5 days as 1-h infusions every 12 h, diluted in 50 mL of normal saline. Serial blood samples were collected at predetermined time points to measure plasma colistin concentrations using a validated liquid chromatography-tandem mass spectrometry method. Renal safety was assessed through serial measurements of serum creatinine, blood urea nitrogen, and renal biomarkers. Serum biomarkers included cystatin C and neutrophil gelatinase-associated lipocalin (NGAL), while urinary biomarkers included clusterin, kidney injury molecule-1, N-acetyl-β-D-glucosaminidase, and NGAL. Results: CMS reached peak levels rapidly with minimal accumulation (accumulation index 0.91 [95% CI, 0.80-1.03]) and a consistent half-life of 2.3 h after both single and multiple dosing, whereas colistin showed progressive accumulation (accumulation index 1.4 [1.32-1.48]) and a half-life increase from 3.6 to 4.5 h. Renal biomarkers, including creatinine, blood urea nitrogen, cystatin C, and NGAL, showed no clinically relevant changes. Although urinary markers were transiently elevated, they remained within reference ranges throughout the study period. Overall, repeated CMS administration was well tolerated, and no evidence of nephrotoxicity was observed. Conclusion: Intravenous administration of CMS resulted in evaluable pharmacokinetic profiles in healthy Korean male volunteers. Although no biomarker-based evidence of nephrotoxicity was detected, these findings should be interpreted with caution, given the small sample size and short study duration. These results may support evidence for renal safety assessments in future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.